Evaluation of iron deposition in the motor CSTC loop of a Chinese family with paroxysmal kinesigenic dyskinesia using quantitative susceptibility mapping
暂无分享,去创建一个
F. Xie | Gaofeng Zhou | Dongcui Wang | Jingyi Tang | Jiuqing Guo | Huashan Lin | Ting Mao | Lin-mei Zhao
[1] Hongjiang Wei,et al. APART-QSM: An improved sub-voxel quantitative susceptibility mapping for susceptibility source separation using an iterative data fitting method , 2023, NeuroImage.
[2] B. Tang,et al. TMEM151A Variants Cause Paroxysmal Kinesigenic Dyskinesia: A Large‐Sample Study , 2021, Movement disorders : official journal of the Movement Disorder Society.
[3] D. Attwell,et al. Astrocyte Ca2+-evoked ATP release regulates myelinated axon excitability and conduction speed , 2021, Science.
[4] Z. Xiong,et al. Cerebellar spreading depolarization mediates paroxysmal movement disorder. , 2021, Cell reports.
[5] Nan-Jie Gong,et al. Decompose quantitative susceptibility mapping (QSM) to sub-voxel diamagnetic and paramagnetic components based on gradient-echo MRI data , 2021, NeuroImage.
[6] J. D. Mills,et al. Seizure-mediated iron accumulation and dysregulated iron metabolism after status epilepticus and in temporal lobe epilepsy , 2021, Acta Neuropathologica.
[7] D. Garcia-Borreguero,et al. Correlation between systemic iron parameters and substantia nigra iron stores in restless legs syndrome. , 2021, Sleep Medicine.
[8] Yuxiang cai,et al. Ferroptosis and Its Role in Epilepsy , 2021, Frontiers in Cellular Neuroscience.
[9] M. Zhang,et al. Brainstem Involvement in Amyotrophic Lateral Sclerosis: A Combined Structural and Diffusion Tensor MRI Analysis , 2021, Frontiers in Neuroscience.
[10] B. Xiao,et al. Novel PRRT2 gene variants identified in paroxysmal kinesigenic dyskinesia and benign familial infantile epilepsy in Chinese families , 2021, Experimental and Therapeutic Medicine.
[11] Zhaoxia Wang,et al. Recommendations for the diagnosis and treatment of paroxysmal kinesigenic dyskinesia: an expert consensus in China , 2021, Translational Neurodegeneration.
[12] Qifu Li,et al. Iron Metabolism and Ferroptosis in Epilepsy , 2020, Frontiers in Neuroscience.
[13] Guangxiang Chen,et al. Neural Mechanisms of Paroxysmal Kinesigenic Dyskinesia: Insights from Neuroimaging , 2020, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[14] A. Lees,et al. Brain iron deposition is linked with cognitive severity in Parkinson’s disease , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[15] Dong Zhou,et al. Altered topological organization of functional brain networks in drug-naive patients with paroxysmal kinesigenic dyskinesia , 2020, Journal of the Neurological Sciences.
[16] Nellie Georgiou-Karistianis,et al. Altered Cortical Morphometry in Pre-manifest Huntington’s Disease: Cross-sectional Data from the IMAGE-HD Study , 2019, 2019 41st Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).
[17] Qiqi Chen,et al. Iron deposition in Parkinson’s disease by quantitative susceptibility mapping , 2019, BMC Neuroscience.
[18] Euan A Ashley,et al. Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy , 2019, PloS one.
[19] Oliver Speck,et al. A robust multi-scale approach to quantitative susceptibility mapping , 2018, NeuroImage.
[20] Chunlei Liu,et al. Longitudinal atlas for normative human brain development and aging over the lifespan using quantitative susceptibility mapping , 2018, NeuroImage.
[21] Yang Li,et al. PRRT2 deficiency induces paroxysmal kinesigenic dyskinesia by regulating synaptic transmission in cerebellum , 2017, Cell Research.
[22] Nian Wang,et al. Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping , 2017, NMR in biomedicine.
[23] Huafu Chen,et al. Thalamocortical dysconnectivity in paroxysmal kinesigenic dyskinesia: Combining functional magnetic resonance imaging and diffusion tensor imaging , 2017, Movement disorders : official journal of the Movement Disorder Society.
[24] Yi Wang,et al. The clinical utility of QSM: disease diagnosis, medical management, and surgical planning , 2017, NMR in biomedicine.
[25] C. Achat-Mendes,et al. Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectator , 2017, Neural regeneration research.
[26] Thomas Walker,et al. Dissociation between iron accumulation and ferritin upregulation in the aged substantia nigra: attenuation by dietary restriction , 2016, Aging.
[27] P. V. van Zijl,et al. Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease , 2016, American Journal of Neuroradiology.
[28] Julio Acosta-Cabronero,et al. In Vivo MRI Mapping of Brain Iron Deposition across the Adult Lifespan , 2016, The Journal of Neuroscience.
[29] B. Tang,et al. Paroxysmal kinesigenic dyskinesia , 2015, Neurology.
[30] Julie C Stout,et al. Iron accumulation in the basal ganglia in Huntington's disease: cross-sectional data from the IMAGE-HD study , 2015, Journal of Neurology, Neurosurgery & Psychiatry.
[31] Dong-Wook Kim,et al. Thalamic involvement in paroxysmal kinesigenic dyskinesia: A combined structural and diffusion tensor MRI analysis , 2015, Human brain mapping.
[32] N. J. Allen,et al. Astrocyte regulation of synaptic behavior. , 2014, Annual review of cell and developmental biology.
[33] Yi Wang,et al. Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker , 2014, Magnetic resonance in medicine.
[34] Robert Turner,et al. Myelin and iron concentration in the human brain: A quantitative study of MRI contrast , 2014, NeuroImage.
[35] A. Lees,et al. Clinical features of childhood‐onset paroxysmal kinesigenic dyskinesia with PRRT2 gene mutations , 2013, Developmental medicine and child neurology.
[36] Q. Gong,et al. Altered intrinsic brain activity in patients with paroxysmal kinesigenic dyskinesia by PRRT2 mutation , 2013, Neurological Sciences.
[37] A. Leemans,et al. Microstructural White Matter Abnormalities and Cognitive Functioning in Type 2 Diabetes , 2012, Diabetes Care.
[38] Ferdinand Schweser,et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study , 2012, NeuroImage.
[39] Ning Wang,et al. Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia , 2011, Nature Genetics.
[40] Mark Hallett,et al. Definition and classification of hyperkinetic movements in childhood , 2010, Movement disorders : official journal of the Movement Disorder Society.
[41] Hehan Tang,et al. Hyperactive putamen in patients with paroxysmal kinesigenic choreoathetosis: A resting‐state functional magnetic resonance imaging study , 2010, Movement disorders : official journal of the Movement Disorder Society.
[42] Hehan Tang,et al. The thalamic ultrastructural abnormalities in paroxysmal kinesigenic choreoathetosis: a diffusion tensor imaging study , 2010, Journal of Neurology.
[43] J. Connor,et al. Iron, the substantia nigra and related neurological disorders. , 2009, Biochimica et biophysica acta.
[44] F. Schmidt. Meta-Analysis , 2008 .
[45] Daniel M. Corcos,et al. Three-dimensional locations and boundaries of motor and premotor cortices as defined by functional brain imaging: A meta-analysis , 2006, NeuroImage.
[46] J. Connor,et al. Iron status and neural functioning. , 2003, Annual review of nutrition.
[47] H. Matsuda,et al. Increased ictal perfusion of the thalamus in paroxysmal kinesigenic dyskinesia , 2001, Journal of neurology, neurosurgery, and psychiatry.
[48] J. Connor,et al. Iron and iron management proteins in neurobiology. , 2001, Pediatric neurology.
[49] A M Graybiel,et al. The basal ganglia and adaptive motor control. , 1994, Science.
[50] B. Hallgren,et al. THE EFFECT OF AGE ON THE NON‐HAEMIN IRON IN THE HUMAN BRAIN , 1958, Journal of neurochemistry.
[51] Yan-zhong Chang,et al. Brain Iron Metabolism and CNS Diseases. , 2019, Advances in experimental medicine and biology.
[52] Fudi Wang,et al. Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders. , 2010, Future medicinal chemistry.